Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 70518-4731

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-4731). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (13)

A text image showing a formula to calculate creatinine clearance (CLcr) based on age, weight, serum creatinine level, and adjusted by a factor for female patients.*

FDA Label Image

2 (2)

A data table showing the formula for adjusting creatinine clearance (CLcr) based on body surface area (BSA). The formula calculates CLcr in mL/min per 1.73m² by multiplying the ratio of CLcr (mL/min) to the subject's BSA (m²) by 1.73.*

FDA Label Image

Levetiracretam Structural Formula (3)

Chemical structure of levetiracetam, depicting its molecular arrangement as a substituted pyrrolidone ring with an ethyl side chain and a carbamoyl group.*

FDA Label Image

Figure 1 (4)

A bar graph comparing the percentage of patients across three groups: placebo (7.4%, N=95), immediate-release levetiracetam tablets 1000 mg/day (37.1%, N=97), and immediate-release levetiracetam tablets 3000 mg/day (39.6%, N=101). Statistically significant differences from placebo are indicated for both levetiracetam groups. The y-axis shows the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 2 (5)

A bar chart comparing the percentage of patients across three groups: Placebo (6.3%, N=111), Immediate-release levetiracetam tablets 1000 mg/day (20.8%, N=106), and Immediate-release levetiracetam tablets 2000 mg/day (35.2%, N=105). Statistically significant differences versus placebo are indicated by asterisks.*

FDA Label Image

Figure 3 (6)

A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam tablets at 3000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4%, with an asterisk indicating statistical significance versus placebo. The y-axis measures the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (7)

Bar chart depicting the percentage of patients for placebo and immediate-release levetiracetam tablets groups. Placebo group (N=97) shows 19.6% of patients, while the immediate-release levetiracetam tablets group (N=101) shows 44.6%, with a noted statistically significant difference versus placebo.*

FDA Label Image

Mm1 (Levetiracetam 750mg 70518 4731 00)

Levetiracetam 750 mg extended-release tablet label from RemedyRepack Inc., packaged in a box of 50 tablets. The label includes storage instructions, a QR code, and mentions repackaging by RemedyRepack in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

Levetiracetam 750 mg extended-release tablet label, film coated, oral dosage form, in a quantity of 1 tablet. The label includes storage instructions, manufacturing details by Solco, and repackaging information by RemedyRepack Inc., Indiana, PA. NDC number is 70518-4731-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.